[go: up one dir, main page]

MX2019010085A - Sulfoximine glycosidase inhibitors. - Google Patents

Sulfoximine glycosidase inhibitors.

Info

Publication number
MX2019010085A
MX2019010085A MX2019010085A MX2019010085A MX2019010085A MX 2019010085 A MX2019010085 A MX 2019010085A MX 2019010085 A MX2019010085 A MX 2019010085A MX 2019010085 A MX2019010085 A MX 2019010085A MX 2019010085 A MX2019010085 A MX 2019010085A
Authority
MX
Mexico
Prior art keywords
sulfoximine
glycosidase inhibitors
glycosidase
inhibitors
tauopathies
Prior art date
Application number
MX2019010085A
Other languages
Spanish (es)
Inventor
S Kulkarni Santosh
Gajendra Giri Awadut
Quattropani Anna
Original Assignee
Asceneuron S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2017/054280 external-priority patent/WO2017144639A1/en
Priority claimed from PCT/EP2017/054268 external-priority patent/WO2017144633A1/en
Application filed by Asceneuron S A filed Critical Asceneuron S A
Publication of MX2019010085A publication Critical patent/MX2019010085A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of formula (I) wherein A, R, W, Q, n and m have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.
MX2019010085A 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors. MX2019010085A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2017/054280 WO2017144639A1 (en) 2016-02-25 2017-02-24 Glycosidase inhibitors
PCT/EP2017/054268 WO2017144633A1 (en) 2016-02-25 2017-02-24 Glycosidase inhibitors
PCT/EP2017/071385 WO2018153508A2 (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors

Publications (1)

Publication Number Publication Date
MX2019010085A true MX2019010085A (en) 2019-11-21

Family

ID=59686981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010085A MX2019010085A (en) 2017-02-24 2017-08-24 Sulfoximine glycosidase inhibitors.

Country Status (5)

Country Link
EP (2) EP3585779A1 (en)
AU (1) AU2017400271B2 (en)
MX (1) MX2019010085A (en)
SG (1) SG11201907774VA (en)
WO (2) WO2018153507A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201701315VA (en) 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
CN108884077A (en) 2016-02-25 2018-11-23 阿森纽荣股份公司 Glycosidase inhibitor
JP2019506430A (en) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム Glycosidase inhibitor
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
WO2017144637A1 (en) 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039027A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Pyrrolidine glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US12195455B2 (en) * 2018-08-22 2025-01-14 Asceneuron Sa Succinate and fumarate acid addition salts of piperazine derivatives
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
WO2025131275A1 (en) 2023-12-20 2025-06-26 Asceneuron Sa (2-(4-(1-(benzo[d]thiazol-5-yl)ethyl)piperazin-1 -yl)pyrimidin-5-yl)(imino)(methyl)-lamda6-sulfanone for use in the treatment of colitis, parkinson disease, tauopathy, als and alzheimer's disease
CN119839282B (en) * 2025-01-22 2025-12-02 安徽大学 A silver nanocluster and its application in methanol detection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL127996C (en) 1963-11-19
DE1595923A1 (en) 1965-02-20 1969-11-27 Merck Ag E 1-Aralkyl-4- (thiazolyl-2) -piperazines and processes for their preparation
CA2308057A1 (en) 1997-10-24 1999-05-06 Neurogen Corporation 1-(2-naphthyl) and 1-(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine d4 receptor subtype ligands
IL158941A0 (en) * 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
US7253168B2 (en) * 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
EP2057171A4 (en) 2006-08-31 2010-04-21 Univ Fraser Simon GLYCOSIDASE SELECTIVE INHIBITORS AND USES THEREOF
JP5525447B2 (en) 2007-10-26 2014-06-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Quinolinone derivatives as PARP inhibitors
EP2890678A4 (en) 2012-08-31 2016-01-27 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
SG11201701315VA (en) 2014-08-28 2017-03-30 Asceneuron Sa Glycosidase inhibitors
WO2017144637A1 (en) * 2016-02-25 2017-08-31 Asceneuron S. A. Acid addition salts of piperazine derivatives
JP2019506430A (en) * 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム Glycosidase inhibitor
CN108884077A (en) * 2016-02-25 2018-11-23 阿森纽荣股份公司 Glycosidase inhibitor

Also Published As

Publication number Publication date
WO2018153508A2 (en) 2018-08-30
AU2017400271A1 (en) 2019-08-22
EP3585783A2 (en) 2020-01-01
AU2017400271B2 (en) 2020-09-24
WO2018153508A3 (en) 2019-02-21
EP3585779A1 (en) 2020-01-01
SG11201907774VA (en) 2019-09-27
WO2018153507A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
MX2018010192A (en) Glycosidase inhibitors.
ZA201701299B (en) Glycosidase inhibitors
MX2019010085A (en) Sulfoximine glycosidase inhibitors.
MX2022012317A (en) Oxysterols and methods of use thereof.
SA520412335B1 (en) Oxy-fluoropiperidine derivatives as kinase inhibitor
SG11201901061QA (en) Heterocyclic compound
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
GEAP201814248A (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
PH12018500061A1 (en) Oxysterols and methods of use thereof
PH12016501338A1 (en) Indazole compounds as irak4 inhibitors
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
SA519402288B1 (en) Pyrimidine compound and pharmaceutical use thereof
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
MY196572A (en) Amino-Methyl Piperidine Derivative as Kinase Inhibitor
MX2022006768A (en) Formulations/compositions comprising a btk inhibitor.
MY193239A (en) Novel b-lactamase inhibitors
PH12016502568B1 (en) Novel heterocyclic compound
MX374568B (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
MX2021003481A (en) Heterocyclic compound.
PH12019502046A1 (en) Pyrrolotriazine derivatives as kinase inhibitor
MX2019015747A (en) Heterocyclic compound.